Drug Costs, Effectiveness, and Kids in the Crossfire: Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis
- PMID: 30803516
- DOI: 10.1016/j.ophtha.2018.12.041
Drug Costs, Effectiveness, and Kids in the Crossfire: Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis
Comment on
-
Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis.Ophthalmology. 2019 Mar;126(3):415-424. doi: 10.1016/j.ophtha.2018.09.043. Epub 2018 Oct 16. Ophthalmology. 2019. PMID: 30336181 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
